Monogram is a leading value-based specialty provider of in-home evidence-based care and benefit management services for patients living with polychronic conditions, including chronic kidney and end-stage renal disease.
Monogram Health is dedicated to improving the well being, quality of life and health outcomes for our patients by partnering with the nation's leading kidney specialists to provide transformative kidney care.
Monogram Health was founded in 2019 by Mike Uchrin and Christopher A. Booker. The company is headquartered in Nashville, with an office in Brentwood, Tennessee.
Monogram deploys an innovative in-home care delivery model and technology-driven array of evidence-based clinical services, including complex case and disease management, utilization management, and medication therapy management to transform the way health care is delivered for those with polychronic conditions.
Monogram uses next generation artificial intelligence algorithms to predict necessary and timely care to promote the delay of Kidney Disease progression, seamless transitions to dialysis and/or pre-emptive kidney transplant, as well as to optimize our patients’ health outcomes once on dialysis.
Monogram partners with health plans to collaborate with nephrologists and ensure high-quality patient care is delivered cost effectively. Monogram currently operates its renal disease benefit management programs and in-home nephrology clinic in nearly 4,000 U.S. cities across 34 states.
Monogram is backed by TPG Capital, Frist Cressey Ventures, CVS Health, Norwest Venture Partners, Cigna Ventures, Humana, Memorial Hermann Health System, SCAN, Heritage Group, Pura Vida Investments, and others. The company closed $375M Series C round on Jan 09, 2023. This brings Monogram's total funding to $547M to date.